CURIS (Stock Symbol: CRIS)
CRIS- Stock Profile
|Stock Ticker (Symbol):||CRIS|
|Traded Exchange:||NASDAQ Stock Exchange|
|Average Traded Price:||$1.37|
|Average Daily Traded Volume:||358,900|
|Started to Trade on:||Friday, July 01, 2011|
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is based in Lexington, Massachusetts.